Determining in which pre-arthritis stage HLA-shared epitope alleles and smoking exert their effect on the development of rheumatoid arthritis

Objectives The human leukocyte antigen-shared epitope (HLA-SE) alleles and smoking are the most prominent genetic and environmental risk factors for rheumatoid arthritis (RA). However, at which pre-arthritis stage (asymptomatic/symptomatic) they exert their effect is unknown. We aimed to determine whether HLA-SE and smoking are involved in the onset of autoantibody positivity, symptoms (clinically suspect arthralgia (CSA)) and/or progression to clinical arthritis. Methods We performed meta-analyses on results from the literature on associations of HLA-SE and smoking with anti-citrullinated protein antibodies (ACPAs) in the asymptomatic population. Next, we studied associations of HLA-SE and smoking with autoantibody positivity at CSA onset and with progression to clinical inflammatory arthritis (IA) during follow-up. Associations in ACPA-positive patients with CSA were validated in meta-analyses with other arthralgia cohorts. Analyses were repeated for rheumatoid factor (RF), anti-carbamylated protein antibodies (anti-CarP) and anti-acetylated protein antibodies (AAPA). Results Meta-analyses showed that HLA-SE is not associated with ACPA positivity in the asymptomatic population (OR 1.06 (95% CI:0.69 to 1.64)), whereas smoking was associated (OR 1.37 (95% CI: 1.15 to 1.63)). At CSA onset, both HLA-SE and smoking associated with ACPA positivity (OR 2.08 (95% CI: 1.24 to 3.49), OR 2.41 (95% CI: 1.31 to 4.43)). During follow-up, HLA-SE associated with IA development (HR 1.86 (95% CI: 1.23 to 2.82)), in contrast to smoking. This was confirmed in meta-analyses in ACPA-positive arthralgia (HR 1.52 (95% CI: 1.08 to 2.15)). HLA-SE and smoking were not associated with RF, anti-CarP or AAPA-positivity at CSA onset. Longitudinally, AAPA associated with IA development independent from ACPA and RF (HR 1.79 (95% CI: 1.02 to 3.16)), anti-CarP did not. Conclusions HLA-SE and smoking act at different stages: smoking confers risk for ACPA and symptom development, whereas HLA-SE mediates symptom and IA development. These data enhance the understanding of the timing of the key risk factors in the development of RA.

[1]  R. Toes,et al.  Do autoantibody-responses mature between presentation with arthralgia suspicious for progression to rheumatoid arthritis and development of clinically apparent inflammatory arthritis? A longitudinal serological study , 2020, Annals of the Rheumatic Diseases.

[2]  A. Vissink,et al.  Arthritis autoantibodies in individuals without rheumatoid arthritis: follow-up data from a Dutch population-based cohort (Lifelines) , 2020, Rheumatology.

[3]  Björn Forsström,et al.  Different Hierarchies of Anti–Modified Protein Autoantibody Reactivities in Rheumatoid Arthritis , 2020, Arthritis & rheumatology.

[4]  L. Abasolo,et al.  A predominant involvement of the triple seropositive patients and others with rheumatoid factor in the association of smoking with rheumatoid arthritis , 2020, Scientific Reports.

[5]  M. Reth,et al.  Antibodies and B cells recognising citrullinated proteins display a broad cross-reactivity towards other post-translational modifications , 2020, Annals of the rheumatic diseases.

[6]  A. H. M. van der Helm-van Mil,et al.  Improvement of symptoms in clinically suspect arthralgia and resolution of subclinical joint inflammation: a longitudinal study in patients that did not progress to clinical arthritis , 2020, Arthritis Research & Therapy.

[7]  E. Karlson,et al.  Impact of Cyclic Citrullinated Peptide Antibody Level on Progression to Rheumatoid Arthritis in Clinically Tested Cyclic Citrullinated Peptide Antibody–Positive Patients Without Rheumatoid Arthritis , 2019, Arthritis care & research.

[8]  W. Robinson,et al.  A Prospective Study of the Development of Inflammatory Arthritis in the Family Members of Indigenous North American People With Rheumatoid Arthritis , 2019, Arthritis & rheumatology.

[9]  C. Terao,et al.  Shared epitope defines distinct associations of cigarette smoking with levels of anticitrullinated protein antibody and rheumatoid factor , 2019, Annals of the rheumatic diseases.

[10]  R. Toes,et al.  Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved sustained DMARD-free status , 2019, Annals of the rheumatic diseases.

[11]  L. Alfredsson,et al.  Complex Relationships of Smoking, HLA–DRB1 Genes, and Serologic Profiles in Patients With Early Rheumatoid Arthritis: Update From a Swedish Population‐Based Case–Control Study , 2019, Arthritis & Rheumatology (Hoboken, N.j.).

[12]  V. Holers,et al.  Nomenclature for the Phases of the Development of Rheumatoid Arthritis. , 2019, Clinical therapeutics.

[13]  B. Zavodovsky,et al.  THE ROLE OF , 2023 .

[14]  L. Trouw,et al.  The risk of individual autoantibodies, autoantibody combinations and levels for arthritis development in clinically suspect arthralgia , 2017, Rheumatology.

[15]  D. Mattey,et al.  Anti-citrullinated protein antibody positive rheumatoid arthritis is primarily determined by rheumatoid factor titre and the shared epitope rather than smoking per se , 2017, PloS one.

[16]  L. Trouw,et al.  Presence of anticitrullinated protein antibodies in a large population-based cohort from the Netherlands , 2017, Annals of the rheumatic diseases.

[17]  D. Symmons,et al.  Smoking is associated with the concurrent presence of multiple autoantibodies in rheumatoid arthritis rather than with anti-citrullinated protein antibodies per se: a multicenter cohort study , 2016, Arthritis Research & Therapy.

[18]  M. Reijnierse,et al.  Clinical factors, anticitrullinated peptide antibodies and MRI-detected subclinical inflammation in relation to progression from clinically suspect arthralgia to arthritis. , 2016, Annals of the rheumatic diseases.

[19]  P. Gregersen,et al.  Associations of Smoking and Age With Inflammatory Joint Signs Among Unaffected First‐Degree Relatives of Rheumatoid Arthritis Patients: Results From Studies of the Etiology of Rheumatoid Arthritis , 2016, Arthritis & rheumatology.

[20]  S. Rantapää-Dahlqvist,et al.  Associations of antibodies against citrullinated peptides with human leukocyte antigen-shared epitope and smoking prior to the development of rheumatoid arthritis , 2015, Arthritis Research & Therapy.

[21]  L. Alfredsson,et al.  Associations With Smoking and Shared Epitope Differ Between IgA‐ and IgG‐Class Antibodies to Cyclic Citrullinated Peptides in Early Rheumatoid Arthritis , 2015, Arthritis & rheumatology.

[22]  J. Norris,et al.  Anti-carbamylated Protein Antibodies Are Present Prior to Rheumatoid Arthritis and Are Associated with Its Future Diagnosis , 2015, The Journal of Rheumatology.

[23]  T. Kawaguchi,et al.  Effects of Smoking and Shared Epitope on the Production of Anti–Citrullinated Peptide Antibody in a Japanese Adult Population , 2014, Arthritis care & research.

[24]  S. Bae,et al.  Gene–environmental interaction between smoking and shared epitope on the development of anti‐cyclic citrullinated peptide antibodies in rheumatoid arthritis: a meta‐analysis , 2014, International journal of rheumatic diseases.

[25]  L. Alfredsson,et al.  Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies , 2014, Annals of the rheumatic diseases.

[26]  P. Emery,et al.  Predicting the development of clinical arthritis in anti-CCP positive individuals with non-specific musculoskeletal symptoms: a prospective observational cohort study , 2014, Annals of the rheumatic diseases.

[27]  J. Bloem,et al.  Characterising arthralgia in the preclinical phase of rheumatoid arthritis using MRI , 2014, Annals of the rheumatic diseases.

[28]  P. Magnusson,et al.  Environmental and genetic factors in the development of anticitrullinated protein antibodies (ACPAs) and ACPA-positive rheumatoid arthritis: an epidemiological investigation in twins , 2013, Annals of the rheumatic diseases.

[29]  Buhm Han,et al.  Imputing Amino Acid Polymorphisms in Human Leukocyte Antigens , 2013, PloS one.

[30]  I. Bruce,et al.  Using lifestyle factors to identify individuals at higher risk of inflammatory polyarthritis (results from the European Prospective Investigation of Cancer-Norfolk and the Norfolk Arthritis Register—the EPIC-2-NOAR Study) , 2013, Annals of the rheumatic diseases.

[31]  D. van Schaardenburg,et al.  A prediction rule for the development of arthritis in seropositive arthralgia patients , 2012, Annals of the rheumatic diseases.

[32]  D. van Schaardenburg,et al.  Smoking and overweight determine the likelihood of developing rheumatoid arthritis , 2012, Annals of the rheumatic diseases.

[33]  A. Barton,et al.  Genetic markers of rheumatoid arthritis susceptibility in anti-citrullinated peptide antibody negative patients , 2012, Annals of the rheumatic diseases.

[34]  L. Alfredsson,et al.  Smoking interacts with HLA-DRB1 shared epitope in the development of anti-citrullinated protein antibody-positive rheumatoid arthritis: results from the Malaysian Epidemiological Investigation of Rheumatoid Arthritis (MyEIRA) , 2012, Arthritis Research & Therapy.

[35]  C. Lewis,et al.  EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis , 2012, Annals of the rheumatic diseases.

[36]  J. Rocklöv,et al.  Clinical and Epidemiological Research , 2022 .

[37]  A. Silman,et al.  UvA-DARE (Digital Academic Repository) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative Aletaha, , 2010 .

[38]  A. Silman,et al.  Rheumatoid arthritis classifi cation criteria : an American College of Rheumatology / European League Against Rheumatism collaborative initiative , 2010 .

[39]  Lars Alfredsson,et al.  Protection against anti-citrullinated protein antibody-positive rheumatoid arthritis is predominantly associated with HLA-DRB1*1301: a meta-analysis of HLA-DRB1 associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in fou , 2010, Arthritis and rheumatism.

[40]  Stephen G. Martin,et al.  Reevaluation of the interaction between HLA-DRB1 shared epitope alleles, PTPN22, and smoking in determining susceptibility to autoantibody-positive and autoantibody-negative rheumatoid arthritis in a large UK Caucasian population. , 2009, Arthritis and rheumatism.

[41]  M. Cheang,et al.  Immunogenetic Risks of Anti-Cyclical Citrullinated Peptide Antibodies in a North American Native Population with Rheumatoid Arthritis and Their First-degree Relatives , 2009, The Journal of Rheumatology.

[42]  B. Dijkmans,et al.  Different properties of ACPA and IgM-RF derived from a large dataset: further evidence of two distinct autoantibody systems , 2009, Arthritis research & therapy.

[43]  B. Dijkmans,et al.  The role of the shared epitope in arthralgia with anti-cyclic citrullinated peptide antibodies (anti-CCP), and its effect on anti-CCP levels , 2007, Annals of the rheumatic diseases.

[44]  B. Prum,et al.  Associations between genetic factors, tobacco smoking and autoantibodies in familial and sporadic rheumatoid arthritis , 2007, Annals of the rheumatic diseases.

[45]  Annette Lee,et al.  Interaction between smoking, the shared epitope, and anti-cyclic citrullinated peptide: a mixed picture in three large North American rheumatoid arthritis cohorts. , 2007, Arthritis and rheumatism.

[46]  Arne Svejgaard,et al.  Strong combined gene-environment effects in anti-cyclic citrullinated peptide-positive rheumatoid arthritis: a nationwide case-control study in Denmark. , 2007, Arthritis and rheumatism.

[47]  S. le Cessie,et al.  The HLA-DRB1 shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide. , 2007, Arthritis and rheumatism.

[48]  Wei Chen,et al.  Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. , 2005, Arthritis and rheumatism.

[49]  S. Cessie,et al.  Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles , 2005, Annals of the rheumatic diseases.

[50]  B. Dijkmans,et al.  Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. , 2004, Arthritis and rheumatism.

[51]  Göran Hallmans,et al.  Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. , 2003, Arthritis and rheumatism.

[52]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[53]  P. Gregersen,et al.  The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. , 1987, Arthritis and rheumatism.

[54]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[55]  L. Alfredsson,et al.  A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. , 2006, Arthritis and rheumatism.